Works matching IS 01676997 AND DT 2007 AND VI 25 AND IP 1

Results: 11

Phase II trial of nolatrexed dihydrochloride [Thymitaq<sup>TM</sup>, AG 337] in patients with advanced hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 85, doi. 10.1007/s10637-006-9003-x

By:

Minaxi Jhawer;
Lee Rosen;
Janet Dancey;
Howard Hochster;
Solomon Hamburg;
Margaret Tempero;
Neil Clendeninn;
Sridhar Mani

Publication type:

Article

Trabectedin (ET-743, Yondelisâ¢) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 1, doi. 10.1007/s10637-006-7773-9

By:

Jan-Hendrik Beumer;
Tessa Buckle;
Mariet Ouwehand;
Niels Franke;
Luis Lopez-Lazaro

Publication type:

Article

Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 69

By:

Lance Heilbrun;
Anthony Shields;
Jawana Lawhorn-Crews;
Karen Baranowski;
Daryn Smith;
Lawrence Flaherty

Publication type:

Article

In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 9, doi. 10.1007/s10637-006-7589-7

By:

Esther Brandon;
Rolf Sparidans;
Ronald van Ooijen;
Irma Meijerman;
Luis Lazaro;
Ignacio Manzanares

Publication type:

Article

Effects of a monoclonal anti-Î±vÎ²3 integrin antibody on blood vesselsâA pharmacodynamic study.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 49, doi. 10.1007/s10637-006-9013-8

By:

Dahua Zhang;
Thomas Pier;
Douglas McNeel;
George Wilding

Publication type:

Article

Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 57, doi. 10.1007/s10637-006-8220-7

By:

Hector Parra;
Raffaele Cavina;
Fiorenza Latteri;
Elisabetta Campagnoli;
Emanuela Morenghi;
Walter Torri;
Giorgio Brambilla;
Marco Alloisio;
Armando Santoro

Publication type:

Article

Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 41, doi. 10.1007/s10637-006-9008-5

By:

Jehana James;
Daryl Murry;
Anthony Treston;
Anna Storniolo;
George Sledge;
Carolyn Sidor;
Kathy Miller

Publication type:

Article

Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 21, doi. 10.1007/s10637-006-7774-8

By:

Marta Monge;
Marta Vilaseca;
Vanessa Soto-Cerrato;
Beatriz Montaner;
Ernest Giralt

Publication type:

Article

Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 63, doi. 10.1007/s10637-006-9006-7

By:

Neelima Denduluri;
James Lee;
Janice Walshe;
Arlene Berman;
Ujala Vatas;
Catherine Chow;
Seth Steinberg;
Michael Cox;
Jennifer Low;
Sandra Swain

Publication type:

Article

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 77

By:

Wei-Ling Hsu

Publication type:

Article

Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

Published in:

Investigational New Drugs, 2007, v. 25, n. 1, p. 31, doi. 10.1007/s10637-006-9000-0

By:

Yasuhiko Kano;
Miyuki Akutsu;
Saburo Tsunoda;
Tohru Izumi;
Hiroyuki Kobayashi;
Hiroyuki Mano;
Yusuke Furukawa

Publication type:

Article